Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Adverse events related to Atricure EPi-Sense Coagulation Device - Analysis of the FDA MAUDE database
  • Aakash Sheth,
  • Zaki Al-Yafeai,
  • Paari Dominic
Aakash Sheth
LSUHSC-S

Corresponding Author:[email protected]

Author Profile
Zaki Al-Yafeai
LSUHSC-S
Author Profile
Paari Dominic
LSUHSC Shreveport
Author Profile

Abstract

Introduction: The Atricure EPi-Sense Device is used for the hybrid convergent procedure, an emerging treatment for persistent atrial fibrillation and long standing persistent atrial fibrillation. However, data on the AE related to the EPi-Sense device are scarce. Methods: Keyword “EPI-SENSE” was searched on the MAUDE database. There were 80 device reports from 2016-2020. After excluding reports when the device was not returned for evaluation, 79 device reports were included for final analysis. Results: The adverse events were broadly classified into 11 categories. The most common complications were pericardial effusion (25.3%), stroke (17.7%) and atrio-esophageal fistula (AEF) (8.9%). Death was reported in 15 (19%) cases, 3 of which were due to pulmonary embolism, 6 due to AEF, 3 due to unknown cause, 1 due to sepsis, 2 due to events related to acute renal failure (ARF). Discussion: Pericardial effusion is a common AE reported in patients with convergence procedure and is well documented in the CONVERGE trial. Convergent procedure is unique in that the epicardial ablations are performed on the posterior wall with the radiofrequency probe directed towards the heart and away from the esophagus which in theory should reduce esophageal injuries. Despite that, a high number of AEF were noticed. Lastly, there were also some reports of saline perfusion malfunction which can lead to injuries due to overheating. Conclusion: This analysis of the AE related to the EPi-Sense device highlights several major adverse events that are previously unreported.
09 Aug 2021Submitted to Journal of Cardiovascular Electrophysiology
10 Aug 2021Submission Checks Completed
10 Aug 2021Assigned to Editor
11 Aug 2021Reviewer(s) Assigned
28 Aug 2021Review(s) Completed, Editorial Evaluation Pending
31 Aug 2021Editorial Decision: Revise Minor
13 Sep 20211st Revision Received
07 Oct 2021Submission Checks Completed
07 Oct 2021Assigned to Editor
07 Oct 2021Reviewer(s) Assigned
20 Oct 2021Review(s) Completed, Editorial Evaluation Pending
20 Oct 2021Editorial Decision: Accept
Feb 2022Published in Journal of Cardiovascular Electrophysiology volume 33 issue 2 on pages 151-153. 10.1111/jce.15287